CASE STUDY Diagnostic Research Program Success PRA’s Planning and Innovation Reduce CostDiagnostic Research Program Success PRA’s Planning and Innovation Reduce Costs Primary Endpoint Develop a prenatal aneuploidy test PRA Services Analysis & Reporting Clinical Operations Data Management Project Management Scientific Leadership/ Consulting Indication Fetal Diagnostic Drug Class Small Molecule Study Phase IV Business Segment Clinical Diagnostic Services Regions United States Western Europe STUDY DESCRIPTION Non-invasive screening for fetal aneuploidy: a new maternal plasma marker A biotechnology company selected PRA Health Sciences’ Clinical Diagnostic Services (CDS) group to conduct a global diagnostic study, which involved validating innovative, non-invasive blood sample

Join for free to read